San Francisco, CA (UroToday.com) — POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana.
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist and associate professor of medicine at Northwestern University in Chicago, Illinois in the United States. I am so excited to have here with me today Dr. Neeraj Agarwal who is a Professor of Medicine and the Director of the GU Oncology […]
Primary adenocarcinoma of the bladder is a rare tumor. It is common in the sixth and seventh decades of life and usually has aggressive behavior. Advanced presentation with or without lymph node metastases is common at the time of diagnosis. Furthermore, pathological diagnosis can be challenging, especially in small biopsy specimens. The molecular landscape of […]
Annual EAU Congresses aim to offer state-of-the-art urological science. The abstracts selected for the 36th edition (EAU21 Virtual) strongly reflect that mission. Due to the high quality of these abstracts, the Scientific Congress Office (SCO) decided to give every accepted abstract its chance in the spotlight during five-day EAU21 Virtual (8-12 July 2021). Over the […]
The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving ongoing androgen deprivation therapy (ADT).
{{header-clinical-trials-navigation}} A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) Condition: Metastatic Castration-Resistant Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04647526 Sponsor: POINT Biopharma Phase: Phase 3 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: Male […]
Small testicular solid lesions are discovered accidentally due to the extensive use of ultrasound in urology and andrology. Early differentiation between benign and malignant testicular neoplasms is crucial for the determination of treatment options, especially for sub-centimetre lesions.
The purpose was to investigate the value of texture analysis in predicting the World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grading of localized clear cell renal cell carcinoma (ccRCC) based on unenhanced CT (UECT).
OBJECTIVE. The purpose of this article is to investigate the oncologic effectiveness and survival outcomes of percutaneous image-guided thermal ablation for clinical T1a renal cell carcinoma (RCC) in patients with other primary nonrenal malignancies.
Combination therapy with docetaxel and androgen deprivation therapy (ADT) prolongs overall survival (OS) in men with metastatic hormone-sensitive prostate cancer. We assessed the benefits and adverse effects of docetaxel and ADT in relation to advancing age.
